



ASX / Media Release

10 November 2025

Board and Officer Appointments and Company Address Change

Invex Therapeutics Limited (**Invex, ASX:IXC, or the Company**) is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury.

Director Appointments

The Company is pleased to announce that following the resignations of Mr David McAuliffe and Dr Thomas Duthy as Directors of the Company (as announced on 7 November 2025), Mr Simon Owen and Professor Warren Harding AM have been appointed as non-executive directors of the Company with immediate effect. As a result of these appointments, the Company confirms that it is now compliant with section 201A(2) of the *Corporations Act 2001* (Cth).

Simon Owen

Simon Owen has over 35 years of experience as a corporate and commercial lawyer and corporate advisor with a particular focus upon developing businesses, innovation and intellectual property and capital markets. He has acted as a chairman and director, both executive and non-executive, for a number of listed and unlisted public companies.

He also has considerable executive experience in the establishment and development of businesses in industries including information technology, biotech, health/medtech, pharmaceuticals, agriculture, blockchain and finance.

From 'start-up' through IPO and beyond, he has engaged not only as a legal and corporate advisor but as a founder, executive, mentor and director for businesses large and small, across a diverse range of industries.

He has acted for investors and venture capital funds as well as participated in nearly 100 separate capital raisings, from seed equity to complex syndicated debt and hybrid raisings in international markets.

His various roles have provided extensive experience in strategic planning, corporate finance, negotiating and structuring transactions, liaising with regulatory authorities and regulatory compliance in jurisdictions around the world.

He regularly contributes time to the earliest stage ventures, incubators and other groups supporting the 'innovation ecosystem' as well as other notable NFP appointments and organisations.

Professor Warren Harding AM

Professor Warren Harding AM is an experienced company director with more than 30 years of leadership experience across global healthcare, biotech and medtech industries. He was Managing Partner in global strategy/ consulting companies Accenture, Deloitte and PWC including Senior Adviser to McKinsey & Co and has extensive experience in corporate governance, strategic transformation and growth. He has been involved in various mergers/acquisitions at a global and national level.

He is Chair of Alzheimer's WA, a NFP addressing the progressive neurological decline of dementia. He is a member of the Finance Audit and Risk Committee and Chairs the Research and Partnership Committee. He was a Government appointed member of the WA Disability Services Commission 2020-24 and is currently a Federal Cabinet appointed Board director of the Australian Digital Health Agency.

He is co-founder and director of two emerging medtech companies involved in real time patient data telemetry and AI enabled alerts; and early digital detection of dementia to enable more timely use of monoclonal antibodies.

Warren holds a Professorship at the School of Medicine, Macquarie University; Bachelor of Science 1st Class Hons, British Council Scholar London School of Economics. He was appointed a Member of the Order of Australia in 2023 for his service to business, technology and community health.

Joint Company Secretary Appointments

The Company is also pleased to welcome Mrs. Carla Healy and Mr. Tim Slate who will jointly act as Company Secretary effective from the date of this announcement.

Mrs. Healy has a Bachelor of Commerce from the University of Western Australia, is a Chartered Accountant and a Graduate of the Australian Institute of Company Directors. With over 20 years of experience in Perth, London and Singapore, she provides accounting and corporate secretarial advice to both private and public companies.

Mr. Slate brings a wealth of experience, with over 15 years in the accounting and company secretarial profession. He has worked across a wide range of multinational corporations and smaller companies in Perth, including ASX and LSE-listed entities, private businesses, and collaborations with high-net-worth individuals. He holds a Bachelor of Commerce from the University of Western Australia, is a Chartered Accountant, an Associate Member of the Governance Institute of Australia and a Graduate of the Australian Institute of Company Directors.

For the purposes of ASX Listing Rule 12.6, the Company confirms that Mrs. Healy will be responsible for communication between the Company and the ASX.

Change of Company Address

Effective 10 November 2025, the Company's address details will change to the following:

Registered Office & Principal Place of Business:

Level 3
101 St Georges Terrace
PERTH WA 6000

Postal Address:

GPO Box 5457
PERTH WA 6831

Telephone: 08 6558 0886

Fax: 08 6316 3337

- ENDS -

This release dated 10 November 2025 has been authorised for lodgement to ASX by the Board of Invex Therapeutics Ltd.

[About Invex Therapeutics Ltd](#)

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.